Advocate Lutheran General Hospital | |
1775 Dempster St, Park Ridge, Illinois 60068 | |
(847) 723-2210 | |
Name | Advocate Lutheran General Hospital |
---|---|
Type | Acute Care Hospital |
Location | 1775 Dempster St, Park Ridge, Illinois |
Ownership | Voluntary non-profit - Church |
Emergency Services | Yes |
Medicare ID (CCN) | 140223 |
NPI Number | 1023308608 |
Organization Name | ADVOCATE LUTHERAN GENERAL HOSPITAL |
Address | 1775 W Dempster St, 8 South, Park Ridge, IL 60068 |
Hospital Type | General Acute Care Hospital - Children |
Phone Number | 847-723-8077 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
NPI Number | 1376709527 |
Organization Name | IRMA ESPOSITO |
Address | 1775 Dempster St, Park Ridge, IL 60068 |
Hospital Type | General Acute Care Hospital |
Phone Number | 123-456-7890 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
NPI Number | 1386779031 |
Organization Name | ADVOCATE LUTHERAN GENERAL |
Address | 1775 Dempster St, Park Ridge, IL 60068 |
Hospital Type | General Acute Care Hospital |
Phone Number | 847-723-7315 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
NPI Number | 1528388634 |
Organization Name | ADVOCATE LUTHERAN GENERAL HOSPITAL |
Address | 1775 W Dempster St, 8 South, Park Ridge, IL 60068 |
Hospital Type | General Acute Care Hospital |
Phone Number | 847-723-5871 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
NPI Number | 1619002284 |
Organization Name | ADVOCATE LUTHERAN GENERAL HOSPITAL |
Address | 1775 Dempster St, Park Ridge, IL 60068 |
Hospital Type | General Acute Care Hospital |
Phone Number | 847-723-7313 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
NPI Number | 1619237203 |
Organization Name | ADVOCATE HEALTH CARE |
Address | 1775 W Dempster St, Park Ridge, IL 60068 |
Hospital Type | General Acute Care Hospital |
Phone Number | 847-723-2210 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
NPI Number | 1699927186 |
Organization Name | ADVOCATE LUTHERAN GENERAL HOSPITAL |
Address | 1775 Dempster St, Park Ridge, IL 60068 |
Hospital Type | General Acute Care Hospital |
Phone Number | 847-723-7748 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
NPI Number | 1891830352 |
Organization Name | LUTHERAN GENERAL HOSPITAL |
Address | 1775 W Dempster St, Park Ridge, IL 60068 |
Hospital Type | Psychiatric Hospital |
Phone Number | 847-723-2210 |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
After more than a year of debate, state regulators ... approved a resolution calling for changes to the healthcare reform law's medical loss ratio provision. The National Association of Insurance Commissioners (NAIC) passed the measure 26-20, over strenuous objections from commissioners who said the process and the resolution itself would undermine the NAIC's reputation.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
The New York Times profiles the challenges that one business owner faced with the health law. Other outlets offer news on the law, including the problems the administration faces in setting up the online marketplaces, concerns about scams targeting consumers and help for Medicare beneficiaries.
Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.
› Verified 5 days ago
Advocate Lutheran General Hospital Acute Care Hospital Location: 1775 Dempster St, Park Ridge, Illinois 60068 Phone: (847) 723-2210 |